1335-54-2

Upstream product

• 75-56-9 methyloxirane 
• 92505-34-5 1-(2-imino-5-methyl-oxazolidin-3-yl)-propan-2-ol 
• 3375-84-6 5-methyl-N-(2-hydroxypropyl)-oxazolidin-2-one 
• 83733-36-2 4,8-dimethyl-2-phenyl-[1,3,6,2]dioxazaborocane 
• 1586805-15-3 C₁₄H₂₁NO₂ 
• 139494-44-3 bis<(2S)-hydroxypropan-1-yl> benzylamine 
• 1302132-86-0 (2R,2'R)-1,1'-(benzylazanediyl)bis(propan-2-ol) 

Downstream Products

• 6288-32-0 2-(2-ethyl-hexanoyloxy)-propionic acid-{bis-[2-(2-ethyl-hexanoyloxy)-propyl]-amide} 
• 93721-41-6 N,N-Bis-(2-hydroxy-propyl)-1-amino-2-hydroxy-2-phenyl-aethan 
• 32656-93-2 9-(2-hydroxy-propyl)-7-methyl-2-phenyl-8,9-dihydro-7H-pyrimido[4,5-e][1,4]oxazepin-5-one 
• 83585-63-1 2-(2-{2-[2-(2-tert-Butoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-2-methyl-propane 
• 78946-83-5 14,18-dimethyl-1,4,7,10,13-pentaoxa-16-azacyclooctadecane 
• 115178-63-7 Benzoic acid [bis-(2-hydroxy-propyl)-carbamoyl]-methyl ester 
• 1639924-58-5 trans-2,5-dimethylmorpholine 
• 1639924-58-5 cis-2,5-dimethylmorpholine 
• 141-91-3 (.+-.)-trans-2,6-dimethyl-morpholine 
• 141-91-3 cis-2,6-dimethylmorpholine 
• 1446419-26-6 C₁₆H₂₁N₃O₃ 
• 1446419-09-5 C₁₆H₂₀N₄O₅ 
• 1357264-90-4 2,2'-(4-((1-butyl-5-cyano-2-hydroxy-4-methyl-6-oxo-1,6-dihydropyridin-3-yl)diazenyl)phenyl-sulfonylazanediyl)bis(propane-2,1-diyl)bis(2-methlacrylate) 
• 1357264-89-1 4-((1-butyl-5-cyano-2-hydroxy-4-methyl-6-oxo-1,6-dihydropyridin-3-yl)diazenyl)-N,N-bis(2-hydroxypropyl)benzenesulfonamide 

Relevant academic research and scientific papers

ZEOLITE CATALYZED PROCESS FOR THE AMINATION OF PROPYLENE OXIDE

The present invention relates to a process for the conversion of propylene oxide to 1-amino-2- propanol and/or di(2-hydroxypropyl)amine comprising (i) providing a catalyst comprising a zeolitic material comprising YO2 and optionally comprising X2O3 in its framework structure, wherein Y is a tetravalent element and X is a trivalent element, wherein the zeolitic material has a framework-type structure selected from the group consisting of MFI and/or MEL, including MEL/MFI intergrowths; (ii) providing a mixture in the liquid phase comprising propylene oxide and ammonia; (iii) contacting the catalyst provided in (i) with the mixture in the liquid phase provided in (ii) for converting propylene oxide to 1-amino-2-propanol and/or di(2-hydroxypropyl)amine.

METHOD FOR PRODUCING CIS- AND TRANS-ENRICHED MDACH

A process for preparing trans-enriched MDACH, including: distilling an MDACH starting mixture in the presence of an auxiliary, which is an organic compound having a molar mass of 62 to 500 g/mol, a boiling point at least 5° C. above the boiling point of cis,cis-2,6-diamino-1-methylcyclohexane, and 2 to 4 functional groups, each of which is independently an alcohol group or a primary, secondary or tertiary amino group. The MDACH starting mixture includes 0 to 100% by weight of 2,4-MDACH and 0 to 100% by weight of 2,6-MDACH, based on the total amount of MDACH present in the MDACH starting mixture. The MDACH starting mixture includes both trans and cis isomers. Trans-enriched MDACH includes 0 to 100% by weight of 2,4-MDACH and 0 to 100% by weight of 2,6-MDACH, where the proportion of trans isomers in the mixture is higher than the proportion of trans isomers in the MDACH starting mixture.

Synthesis of pyrrole N-derivatives from oxazolidines

Transformations of oxazolidine derivatives synthesized from industrially produced amino alcohols, aldehydes, and ketones under basic or acidic catalysis lead to the formation of N-alkyl- and N-(hydroxyalkyl)-substituted pyrroles in 19-81% yields.

Structure and reactivity of a preactivated sp2-sp3 diboron reagent: Catalytic regioselective boration of α,β-unsaturated conjugated compounds

A novel sp2-sp3 diboron reagent has been developed for the copper-catalyzed β-boration of α,β-unsaturated conjugated compounds. The reaction proceeds under mild conditions with various substrates, i.e., α,β-unsaturated esters, ketones, nitriles, ynones, amides, and aldehydes, in the absence of additives such as phosphine and sodium tert-butoxide to provide β-borylhomoenolates in good to excellent yields. The presence of an sp3-hybridized boron center, unambigously confirmed by X-ray crystallography, sufficiently activates the unsymmetrical pinacolato diisopropanolaminato diboron (PDIPA diboron, 2) to transfer the sp2-hybridized boron moiety chemoselectively. These observations suggest that the activation of one of the boron atoms is an essential step in the Cu-catalyzed β-boration catalytic cycle.

Process for improving the conversion of oxazolidones to alkanolamines

There is provided a regeneration process for converting oxazolidones such as hydroxypropyloxazolidone (HPOZD) to alkanolamines such as di-isopropanolamine (DIPA) and CO2. An amine stream containing HPOZD joins a stream that includes a caustic solution. The combined stream is passed to a tank where the caustic reacts with HPOZD to convert it to DIPA and CO2. The conversion of HPOZD to DIPA and CO2 requires a ratio of at least 2 moles of hydroxide for each mole of HPOZD in the solution. The conversion reaction is carried out in a reaction vessel at a temperature above 60° C. The reaction mixture is held in a feed tank for approximately 2 hours while being constantly mixed. After the reaction is completed, the mixture is allowed to settle which results in the virtually complete separation of the amine phase (containing DIPA, and water) from the caustic phase. After an appropriate settling interval, a portion of the caustic phase is drawn from the reaction mixture as a waste/neutralization stream while the other portion of the caustic phase and a very small portion of the amine phase may be sent to a recycle tank for use in subsequent reaction steps. The majority of the amine phase is treated using ion exchange resins to remove excess cations from the amine and clean amine is returned to the amine system.

Process for improving the conversion of oxazolidones to alkanolamines

There is provided a regeneration process for converting oxazolidones such as hydroxypropyloxazolidone (HPOZD) to alkanolamines such as diisopropanolamine (nIPA) and CO2. An amine stream containing HPOZD joins a stream that includes a caustic solution. The combined stream is passed to a tank where the caustic reacts with HPOZD to convert it to DIPA and CO2. The conversion of HPOZD to DIPA and CO2 requires a ratio of at least 2 moles of hydroxide for each tnole of HPOZD in the solution. The conversion reaction is carried out in a reaction vessel at a temperature above 60°C. The reaction mixture is held in a feed tank for approximately 2 hours while being ccmstantly mixed. After the reaction is completed, the mixture is allowed to settle which results in the virtually complete separation of the amine phase (containing DIPA, and water) from the caustic phase. After an appropriate settling interval, a portion of the caustic phase is drawn from the reaction mixture as a waste/neutralization stream while the other portion of the caustic phase and a very small portion of the amine phase may be sent to a recycle tank for use in subsequent reaction steps. The majority of the amine phase is treated using ion exchange resins to remove excess cations from the amine and clean amine is returned to the amine system.

Pyrithione biocides enhanced by zinc metal ions and organic amines

The present invention is directed to a stable, soluble, antimicrobial composition concentrate comprising pyrithione or a pyrithione complex in an amount of from about 0.5% to about 30 weight percent, a zinc source in an amount of from about 0.1% to about 10%, and an organic amine component in an amount of from about 30% to about 80%, said percents being based upon the total weight of the composition concentrate. The invention is also directed to methods of controlling the growth of free-living microorganisms or biofilms using the antimicrobial composition of the invention, and products made using the antimicrobial composition of the invention.

Cytokine potentiator and pharmaceutical formulation for cytokine administration

A cytokine activity enhancer comprising an ethanolamine derivative of the following general formula (I) or a salt thereof, or comprising it along with cytokine or a cytokine production promoter; and also a medicine for diseases with lowered cytokine activity, comprising, as the active ingredient, the cytokine activity enhancer: STR1 wherein R1 is H, --CH3, --CH2 CH(CH3)OH or --CH2 CH2 OH; R2 is H, --CH3, --CH2 CH3 or --COOH; and R3 is H, --CH3, --CH2 CH3 or --CH2 NH2.

Scavenger assisted combinatorial process for preparing libraries of amides, carbamates and sulfonamides

This invention relates to a novel solution phase process for the preparation of amide, carbamate, and sulfonamide combinatorial libraries. These libraries have utility for drug discovery and are used to form wellplate components of novel assay kits.

Synthesis of Chiral Lithium Dialkoxyaminoborohydrides

A convenient synthesis of chiral dialkoxyaminoborohydrides from borane and some diethanolamines is described.Tis is a novel class of reducing agents which react with acetophenone to afford α-methyl benzyl alcohol in good yields but in low ee's.